IN2014CN02971A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02971A
IN2014CN02971A IN2971CHN2014A IN2014CN02971A IN 2014CN02971 A IN2014CN02971 A IN 2014CN02971A IN 2971CHN2014 A IN2971CHN2014 A IN 2971CHN2014A IN 2014CN02971 A IN2014CN02971 A IN 2014CN02971A
Authority
IN
India
Prior art keywords
formula
compound
alkyl
halo
orn
Prior art date
Application number
Other languages
English (en)
Inventor
Jo Ann Wilson
Sriram Naganathan
Matthew Pfeiffer
Neil G Andersen
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of IN2014CN02971A publication Critical patent/IN2014CN02971A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/233Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/02Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/57Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/58Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/57Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/59Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/90Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN2971CHN2014 2011-10-20 2012-10-22 IN2014CN02971A (enrdf_load_html_response)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161549312P 2011-10-20 2011-10-20
PCT/US2012/061320 WO2013059788A1 (en) 2011-10-20 2012-10-22 Process for preparing quinoline derivatives

Publications (1)

Publication Number Publication Date
IN2014CN02971A true IN2014CN02971A (enrdf_load_html_response) 2015-07-03

Family

ID=47146705

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2971CHN2014 IN2014CN02971A (enrdf_load_html_response) 2011-10-20 2012-10-22

Country Status (23)

Country Link
US (3) US9365516B2 (enrdf_load_html_response)
EP (1) EP2768796B1 (enrdf_load_html_response)
JP (2) JP6208140B2 (enrdf_load_html_response)
KR (1) KR102075371B1 (enrdf_load_html_response)
CN (2) CN104395284A (enrdf_load_html_response)
AR (1) AR088483A1 (enrdf_load_html_response)
AU (2) AU2012325768B2 (enrdf_load_html_response)
BR (1) BR112014009302B1 (enrdf_load_html_response)
CA (1) CA2852771C (enrdf_load_html_response)
DK (1) DK2768796T3 (enrdf_load_html_response)
EA (1) EA031485B1 (enrdf_load_html_response)
ES (1) ES2765013T3 (enrdf_load_html_response)
GE (1) GEP20207110B (enrdf_load_html_response)
HU (1) HUE048023T2 (enrdf_load_html_response)
IL (1) IL232139A (enrdf_load_html_response)
IN (1) IN2014CN02971A (enrdf_load_html_response)
MX (1) MX343288B (enrdf_load_html_response)
PL (1) PL2768796T3 (enrdf_load_html_response)
PT (1) PT2768796T (enrdf_load_html_response)
TW (2) TWI642650B (enrdf_load_html_response)
UA (1) UA116876C2 (enrdf_load_html_response)
WO (1) WO2013059788A1 (enrdf_load_html_response)
ZA (1) ZA201402579B (enrdf_load_html_response)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2593090T3 (pl) 2010-07-16 2022-02-21 Exelixis, Inc. Kompozycje farmaceutyczne modulatora c-Met
CN103402505A (zh) 2010-09-27 2013-11-20 埃克塞里艾克西斯公司 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
EP2673262B1 (en) 2011-02-10 2021-11-03 Exelixis, Inc. Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
TW201806598A (zh) 2011-05-02 2018-03-01 艾克塞里克斯公司 治療癌症及骨癌疼痛之方法
KR20140069133A (ko) 2011-09-22 2014-06-09 엑셀리시스, 인코포레이티드 골다공증의 치료방법
ES2765013T3 (es) * 2011-10-20 2020-06-05 Exelixis Inc Procedimiento para preparar derivados de quinolina
HK1207587A1 (en) 2012-05-02 2016-02-05 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
US10273211B2 (en) 2013-03-15 2019-04-30 Exelixis, Inc. Metabolites of N-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
EP2981263B1 (en) 2013-04-04 2022-06-29 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
CN104649969B (zh) * 2013-11-22 2019-02-12 广东东阳光药业有限公司 一种替尼类药物的盐及其制备方法
AU2015218236B2 (en) 2014-02-14 2019-06-13 Exelixis, Inc. Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
CN106255499A (zh) 2014-03-17 2016-12-21 埃克塞里艾克西斯公司 卡博替尼制剂的给药
CN104788372B (zh) * 2014-07-25 2018-01-30 上海圣考医药科技有限公司 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
CN106715397B (zh) 2014-07-31 2021-07-23 埃克塞里艾克西斯公司 制备氟-18标记的卡博替尼及其类似物的方法
WO2016022697A1 (en) 2014-08-05 2016-02-11 Exelixis, Inc. Drug combinations to treat multiple myeloma
CN108026035B (zh) * 2015-09-02 2021-03-30 陈昆锋 具有蛋白酪氨酸磷酸酶shp-1激动剂活性的化合物
RU2748549C2 (ru) 2016-04-15 2021-05-26 Экселиксис, Инк. Способ лечения почечно-клеточного рака с использованием n-(4-(6,7-диметоксихинолин-4-илокси)фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, (2s)-гидроксибутандиоата
CN109836382B (zh) * 2017-11-29 2021-11-05 江苏豪森药业集团有限公司 苹果酸卡博替尼及其中间体的制备方法
SG11202006921PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
CN115192540A (zh) 2018-06-15 2022-10-18 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
CN112142619B (zh) * 2020-10-20 2023-01-10 浙江工业大学 一种1,1-环丙烷二羧酸酰胺类化合物及其制备方法和应用
WO2022201079A1 (en) * 2021-03-24 2022-09-29 Biocon Limited Process for preparation of cabozantinib
WO2024111001A1 (en) * 2022-11-25 2024-05-30 Msn Laboratories Private Limited, R&D Center Crystalline forms of n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide fumarate and process for its preparation
AU2024215796A1 (en) 2023-01-31 2025-05-15 Handa Oncology, Llc Improved cabozantinib compositions and methods of use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE520403T1 (de) 2003-09-26 2011-09-15 Exelixis Inc N-ä3-fluoro-4-(ä6-(methyloxy)-7-ä(3-morpholin-4 ylpropyl)oxyüquinolin-4-ylüoxy)phenylü-n'-(4- fluorophenyl)cyclopropane-1,1-dicarboxamid zur behandlung von krebs
JP5368701B2 (ja) * 2004-07-02 2013-12-18 エクセリクシス、インコーポレイテッド c−Metモジュレーター及び使用方法
EP1874759A4 (en) 2005-04-06 2009-07-15 Exelixis Inc C-MET MODULATORS MODULATORS AND METHODS OF USE
PL2101759T3 (pl) 2006-12-14 2019-05-31 Exelixis Inc Sposoby stosowania inhibitorów MEK
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
WO2009136663A1 (en) * 2008-05-08 2009-11-12 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
TW201035017A (en) * 2008-09-26 2010-10-01 Smithkline Beecham Corp Preparation of a quinolinyloxydiphenylcyclopropanedicarboxamide
US20130197230A1 (en) * 2008-11-13 2013-08-01 Jo Ann Wilson Methods of preparing quinoline derivatives
CN102239148A (zh) 2008-12-04 2011-11-09 埃克塞里艾克西斯公司 喹啉衍生物的制备方法
CN106083714B (zh) * 2009-01-16 2019-11-26 埃克塞里艾克西斯公司 N-(4-{[6,7-双(甲基氧基)喹啉-4-基]氧基}苯基)-n′-(4-氟苯基)环丙烷-1,1-二甲酰胺苹果酸盐及其结晶型
AU2010274012A1 (en) 2009-07-17 2012-02-09 Exelixis, Inc. Crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy] -quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
TW201202228A (en) 2010-03-12 2012-01-16 Exelixis Inc Hydrated crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
PL2593090T3 (pl) 2010-07-16 2022-02-21 Exelixis, Inc. Kompozycje farmaceutyczne modulatora c-Met
EP2593091A1 (en) 2010-07-16 2013-05-22 Exelixis, Inc. C-met modulator pharmaceutical compositions
CA2812753A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
CN103402505A (zh) 2010-09-27 2013-11-20 埃克塞里艾克西斯公司 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
CA2812744A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
US20130252956A1 (en) 2010-11-22 2013-09-26 Howard Kallender Methods of treating cancer
EP2673262B1 (en) 2011-02-10 2021-11-03 Exelixis, Inc. Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
TW201806598A (zh) 2011-05-02 2018-03-01 艾克塞里克斯公司 治療癌症及骨癌疼痛之方法
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法
KR20140069133A (ko) 2011-09-22 2014-06-09 엑셀리시스, 인코포레이티드 골다공증의 치료방법
ES2765013T3 (es) 2011-10-20 2020-06-05 Exelixis Inc Procedimiento para preparar derivados de quinolina
KR20140088610A (ko) 2011-11-08 2014-07-10 엑셀리시스, 인코포레이티드 암을 치료하기 위한 met 및 vegf의 이중 저해제
HK1207587A1 (en) 2012-05-02 2016-02-05 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
WO2014039971A1 (en) 2012-09-07 2014-03-13 Exelixis, Inc. Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma

Also Published As

Publication number Publication date
US20160229805A1 (en) 2016-08-11
JP2017222648A (ja) 2017-12-21
TW201731812A (zh) 2017-09-16
CN110511158A (zh) 2019-11-29
TW201321342A (zh) 2013-06-01
NZ624328A (en) 2016-10-28
MX343288B (es) 2016-11-01
UA116876C2 (uk) 2018-05-25
BR112014009302B1 (pt) 2020-04-28
PT2768796T (pt) 2020-02-21
EP2768796B1 (en) 2019-11-20
EA031485B1 (ru) 2019-01-31
HK1201517A1 (en) 2015-09-04
IL232139A0 (en) 2014-05-28
ES2765013T3 (es) 2020-06-05
NZ723880A (en) 2018-03-23
BR112014009302A2 (pt) 2017-05-23
WO2013059788A1 (en) 2013-04-25
CA2852771A1 (en) 2013-04-25
MX2014004583A (es) 2014-10-06
US20180230100A1 (en) 2018-08-16
US9365516B2 (en) 2016-06-14
TWI642650B (zh) 2018-12-01
KR20140088874A (ko) 2014-07-11
EP2768796A1 (en) 2014-08-27
ZA201402579B (en) 2015-03-25
DK2768796T3 (da) 2020-02-24
CA2852771C (en) 2019-11-26
KR102075371B1 (ko) 2020-02-10
JP2014530880A (ja) 2014-11-20
JP6208140B2 (ja) 2017-10-04
AU2012325768A1 (en) 2014-05-22
HUE048023T2 (hu) 2020-05-28
US20140256938A1 (en) 2014-09-11
IL232139A (en) 2017-11-30
GEAP201913471A (en) 2019-10-25
AU2017254982A1 (en) 2017-11-23
CN104395284A (zh) 2015-03-04
TWI619694B (zh) 2018-04-01
EA201490831A1 (ru) 2014-09-30
PL2768796T3 (pl) 2020-05-18
US9969692B2 (en) 2018-05-15
GEP20207110B (en) 2020-05-25
AU2012325768B2 (en) 2017-08-10
AR088483A1 (es) 2014-06-11

Similar Documents

Publication Publication Date Title
IN2014CN02971A (enrdf_load_html_response)
MX352470B (es) Disales de acido malonico y metodo para preparar dihaluros de malonilo.
PH12016502334B1 (en) Method for producing fused heterocyclic compound
IN2014MN01521A (enrdf_load_html_response)
EP2681204A4 (en) SYNTHESIS OF INTERMEDIATE PRODUCTS FOR TREPROSTINE PRODUCTION
MX2018007106A (es) Metodo de produccion de un derivado de amida aromatica.
IN2014DN00144A (enrdf_load_html_response)
NZ601805A (en) Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same
IN2014MN00976A (enrdf_load_html_response)
UA111868C2 (uk) Спосіб одержання естерів (5-фтор-2-метил-3-хінолін-2-ілметиліндол-1-іл)-оцтової кислоти
PH12011000224A1 (en) Synthesis of rare earth metal extractant
IN2015DN00665A (enrdf_load_html_response)
MX2014003638A (es) Cristal de hidrato 5-hidroxi-1h-imidazol-4-carboxamida-3/4, metodo para producir el mismo y cristal de hidrato de 5-hidroxi-1h-imidazol-4-carboxamida.
WO2011102640A3 (en) Method for preparing sitagliptin and amine salt intermediates used therein
MX337997B (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
IN2012DN00361A (enrdf_load_html_response)
MX2013008595A (es) Procedimiento mejorado para la preparacion de 2,2-difluoroetilamina.
UA113067C2 (xx) Спосіб одержання хінолінкарбонової кислоти
UA111329C2 (uk) Спосіб синтезу івабрадину і його адитивних солей з фармацевтично прийнятною кислотою
IN2014CN04123A (enrdf_load_html_response)
IN2014DN05745A (enrdf_load_html_response)
BR112013018809A8 (pt) Processo para produção de derivados de ácido amidocarboxílico aromático
MX2014008995A (es) Compuesto novedoso de ester de acido acetico o una sal del mismo.
NZ709587A (en) Method for preparing cyclopropane derivatives
GEP20156369B (en) New process for synthesis of ivabradine and addition salts therewith pharmaceutically acceptable acid